Sign up
Log in
News
LUCD
0.8500
-1.16%
-0.0100
Weekly Report: what happened at LUCD last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at LUCD last week (0708-0712)?
Weekly Report · 07/15 11:52
Weekly Report: what happened at LUCD last week (0701-0705)?
Weekly Report · 07/08 11:54
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
NASDAQ · 07/04 15:29
LUCID DIAGNOSTICS ANNOUNCES POSITIVE DATA FROM ITS ESOGUARD BE-1 PROSPECTIVE, INTERNATIONAL, MULTICENTER CLINICAL VALIDATION STUDY OF ESOGUARD® ESOPHAGEAL PRECANCER TESTING IN A SCREENING POPULATION
Reuters · 07/02 11:55
Lucid Diagnostics files to sell 72.4M shares by holders
Seeking Alpha · 07/01 21:41
LUCID DIAGNOSTICS INC FILES FOR OFFERING OF UP TO 72.4 MLN SHARES BY THE SELLING STOCKHOLDERS - SEC FILING
Reuters · 07/01 21:27
Weekly Report: what happened at LUCD last week (0624-0628)?
Weekly Report · 07/01 11:55
Weekly Report: what happened at LUCD last week (0617-0621)?
Weekly Report · 06/24 12:05
LUCID DIAGNOSTICS INC -RECEIVED NOTICE FROM NASDAQ, NOTIFIED FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD BY CO'S COMMON STOCK
Reuters · 06/21 21:18
Weekly Report: what happened at LUCD last week (0610-0614)?
Weekly Report · 06/17 11:54
Lucid Diagnostic Reports 4,000 Firefighter Undergoes EsoGuard Esophageal Precancer Testing
Benzinga · 06/12 12:11
Weekly Report: what happened at LUCD last week (0603-0607)?
Weekly Report · 06/10 11:57
Lucid Diagnostics Is Maintained at Buy by Ascendiant Capital
Dow Jones · 06/06 17:24
Lucid Diagnostics Price Target Cut to $7.50/Share From $8.00 by Ascendiant Capital
Dow Jones · 06/06 17:24
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Lowers Price Target to $7.5
Benzinga · 06/06 17:14
Lucid Diagnostics Inc.: Other definitive proxy statementsOpen document
Press release · 06/06 14:19
Buy Rating Affirmed for Lucid Diagnostics Amidst Promising Products and Substantial Market Opportunity
TipRanks · 06/06 09:55
U.S. RESEARCH ROUNDUP-Chord Energy, PVH, Saia
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. Chord Energy, PVH, Saia and Costco raise their ratings and target prices. Adobe, Campbell Soup and AT&T among companies with target price cuts by Wall Street analysts.
Reuters · 06/06 07:13
LUCID DIAGNOSTICS INC <LUCD.O>: ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $7.5 FROM $8
Reuters · 06/06 04:43
More
Webull provides a variety of real-time LUCD stock news. You can receive the latest news about Lucid Diagnostics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LUCD
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.